Esclerose lateral amiotrófica em Belo Horizonte, Brasil entre 2010 e 2020: um estudo clínico epidemiológico
DOI:
https://doi.org/10.11606/issn.2317-0190.v29i4a199833Palavras-chave:
Esclerose Amiotrófica Lateral, Fatores Epidemiológicos, Estudo Clínico, BrasilResumo
Objetivo: Descrever o perfil clínico de indivíduos com Esclerose Lateral Amiotrófica (ELA) de um hospital de referência na cidade de Belo Horizonte, Brasil. Métodos: Trata-se de um estudo transversal retrospectivo com coleta de dados de prontuários eletrônicos de indivíduos com diagnóstico definido de ELA entre 2010 e 2020, no setor de referência em Distrofias Musculares de um hospital de uma capital brasileira. Resultados: Foram incluídos 103 indivíduos com ELA, com idade média de 60±12 anos, idade média de diagnóstico de 56±12 anos e tempo médio de evolução da doença de 3±3 anos. Além disso, 70% eram do sexo masculino, 88% com ELA esporádica, com envolvimento bulbar semelhante entre leve (32%), moderado (27%) e grave (28%), e com maior taxa de diagnóstico de 50 a 70 anos de idade. Conclusão: Os dados epidemiológicos deste estudo são muito semelhantes aos da literatura. No entanto, a heterogeneidade da doença, a complexidade do diagnóstico e a diversidade de formas que cada estudo traz para a doença, e principalmente a rápida progressão, dificultam a discussão de um quadro mais extenso. Traçar esse perfil é importante para uma clínica mais focada e um manejo mais adequado, e para isso são necessários mais estudos.
Downloads
Referências
Kiernan MC, Vucic S, Cheah BC, Turner MR, Eisen A, Hardiman O, et al. Amyotrophic lateral sclerosis. Lancet. 2011;377(9769):942-55. Doi: https://doi.org10.1016/S0140-6736(10)61156-7
Factor-Litvak P, Al-Chalabi A, Ascherio A, Bradley W, Chío A, Garruto R, et al. Current pathways for epidemiological research in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2013;14 Suppl 1(Suppl 1):33-43. Doi: https://doi.org10.3109/21678421.2013.778565
Hardiman O, Al-Chalabi A, Chio A, Corr EM, Logroscino G, Robberecht W, et al. Amyotrophic lateral sclerosis. Nat Rev Dis Primers. 2017;3:17071. Doi: https://doi.org/10.1038/nrdp.2017.71
Calvo A, Vasta R, Moglia C, Matteoni E, Canosa A, Mattei A, et al. Prognostic role of slow vital capacity in amyotrophic lateral sclerosis. J Neurol. 2020;267(6):1615-21. Doi: https://doi.org/10.1007/s00415-020-09751-1
Calvo AC, Manzano R, Mendonça DM, Muñoz MJ, Zaragoza P, Osta R. Amyotrophic lateral sclerosis: a focus on disease progression. Biomed Res Int. 2014;2014:925101. Doi: https://doi.org/10.1155/2014/925101
Wijesekera LC, Leigh PN. Amyotrophic lateral sclerosis. Orphanet J Rare Dis. 2009;4:3. Doi: https://doi.org/10.1186/1750-1172-4-3
Marin B, Boumédiene F, Logroscino G, Couratier P, Babron MC, Leutenegger AL, et al. Variation in worldwide incidence of amyotrophic lateral sclerosis: a meta-analysis. Int J Epidemiol. 2017;46(1):57-74. Doi: https://doi.org/10.1093/ije/dyw061
Moura MC, Casulari LA, Carvalho Garbi Novaes MR. Ethnic and demographic incidence of amyotrophic lateral sclerosis (ALS) in Brazil: A population based study. Amyotroph Lateral Scler Frontotemporal Degener. 2016;17(3-4):275-81. doi: https://doi.org/10.3109/21678421.2016.1140210
Dietrich-Neto F, Callegaro D, Dias-Tosta E, Silva HA, Ferraz ME, Lima JM, Oliveira AS. Amyotrophic lateral sclerosis in Brazil: 1998 national survey. Arq Neuropsiquiatr. 2000;58(3A):607-15. Doi: https://doi.org/10.1590/s0004-282x2000000400002
Palese F, Sartori A, Verriello L, Ros S, Passadore P, Manganotti P, et al. Epidemiology of amyotrophic lateral sclerosis in Friuli-Venezia Giulia, North-Eastern Italy, 2002-2014: a retrospective population-based study. Amyotroph Lateral Scler Frontotemporal Degener. 2019;20(1-2):90-9. Doi: https://doi.org/10.1080/21678421.2018.1511732
Raymond J, Oskarsson B, Mehta P, Horton K. Clinical characteristics of a large cohort of US participants enrolled in the National Amyotrophic Lateral Sclerosis (ALS) Registry, 2010-2015. Amyotroph Lateral Scler Frontotemporal Degener. 2019;20(5-6):413-20. Doi: https://doi.org/10.1080/21678421.2019.1612435
Jun KY, Park J, Oh KW, Kim EM, Bae JS, Kim I, Kim SH. Epidemiology of ALS in Korea using nationwide big data. J Neurol Neurosurg Psychiatry. 2019;90(4):395-403. Doi: https://doi.org/10.1136/jnnp-2018-318974
Longinetti E, Fang F. Epidemiology of amyotrophic lateral sclerosis: an update of recent literature. Curr Opin Neurol. 2019;32(5):771-6. Doi: https://doi.org/10.1097/WCO.0000000000000730
Castro-Costa CM, Oriá RB, Machado-Filho JA, Franco MT, Diniz DL, Giffoni SD, et al. Amyotrophic lateral sclerosis. Clinical analysis of 78 cases from Fortaleza (northeastern Brazil). Arq Neuropsiquiatr. 1999;57(3B):761-74. Doi: https://doi.org/10.1590/s0004-282x1999000500006
Castro-Costa CM, Oriá RB, Vale OC, Arruda JA, Horta WG, et al. Motor neuron diseases in the university hospital of Fortaleza (Northeastern Brazil): a clinico-demographic analysis of 87 cases. Arq Neuropsiquiatr. 2000;58(4):986-9. Doi: https://doi.org/10.1590/s0004-282x2000000600002
Werneck LC, Bezerra R, Silveira Neto Od, Scola RH. A clinical epidemiological study of 251 cases of amyotrophic lateral sclerosis in the south of Brazil. Arq Neuropsiquiatr. 2007;65(2A):189-95. Doi: https://doi.org/10.1590/s0004-282x2007000200001
Linden-Junior E, Becker J, Schestatsky P, Rotta FT, Marrone CD, Gomes I. Prevalence of amyotrophic lateral sclerosis in the city of Porto Alegre, in Southern Brazil. Arq Neuropsiquiatr. 2013;71(12):959-62. Doi: https://doi.org/10.1590/0004-282X20130177
Matos SE, Conde MT, Fávero FM, Taniguchi M, Quadros AA, Fontes SV, Oliveira AS. Mortality rates due to amyotrophic lateral sclerosis in São Paulo City from 2002 to 2006. Arq Neuropsiquiatr. 2011;69(6):861-6. Doi: https://doi.org/10.1590/s0004-282x2011000700002
Lima NM, Nucci A. Clinical attention and assistance profile of patients with amyotrophic lateral sclerosis. Arq Neuropsiquiatr. 2011;69(2A):170-5. Doi: https://doi.org/10.1590/s0004-282x2011000200005
Loureiro MP, Gress CH, Thuler LC, Alvarenga RM, Lima JM. Clinical aspects of amyotrophic lateral sclerosis in Rio de Janeiro/Brazil. J Neurol Sci. 2012;316(1-2):61-6. Doi: https://doi.org/10.1016/j.jns.2012.01.029
Moura MC, Novaes MR, Eduardo EJ, Zago YS, Freitas Rdel N, Casulari LA. Prognostic Factors in Amyotrophic Lateral Sclerosis: A Population-Based Study. PLoS One. 2015;10(10):e0141500. Doi: https://doi.org/10.1371/journal.pone.0141500
Instituto Brasileiro de Geografia e Estatística. Brazil; Octuber 12, 2015 [texto na Internet]. Rio de Janeiro: IBGE; c2021 [citado 2021 Maio 23]. Disponível em: http://www.ibge.gov.br
Morais LC, Valle MHF, Pessoa BP, Polese JC. Perfil epidemiológico, função pulmonar e incidência de hipoventilação dos pacientes com Esclerose Lateral Amiotrófica de um hospital referência de uma capital brasileira: um estudo transversal retrospectivo. Rev Conexão Ciên. 2020;15(2):93-102.
Prado LG, Bicalho IC, Vidigal-Lopes M, Ferreira CJ, Mageste Barbosa LS, Gomez RS, et al. Amyotrophic lateral sclerosis in Brazil: Case series and review of the Brazilian literature. Amyotroph Lateral Scler Frontotemporal Degener. 2016;17(3-4):282-8. Doi: https://doi.org/10.3109/21678421.2016.1143011
Prado LGR, Rocha NP, Souza LC, Bicalho ICS, Gomez RS, Vidigal-Lopes M, et al. Longitudinal assessment of clinical and inflammatory markers in patients with amyotrophic lateral sclerosis. J Neurol Sci. 2018;394:69-74. Doi: https://doi.org/10.1016/j.jns.2018.08.033
Tandan R, Bradley WG. Amyotrophic lateral sclerosis: Part 1. Clinical features, pathology, and ethical issues in management. Ann Neurol. 1985;18(3):271-80. Doi: https://doi.org/10.1002/ana.410180302
World Health Organization. Physical status: the use and interpretation of antropometry. Geneve: WHO; 1995. [WHO Technical Report Series, 854].
Pupillo E, Messina P, Logroscino G, Beghi E; SLALOM Group. Long-term survival in amyotrophic lateral sclerosis: a population-based study. Ann Neurol. 2014;75(2):287-97. Doi: https://doi.org/10.1002/ana.24096
Aguila MA, Longstreth WT Jr, McGuire V, Koepsell TD, van Belle G. Prognosis in amyotrophic lateral sclerosis: a population-based study. Neurology. 2003;60(5):813-9. Doi: https://doi.org/10.1212/01.wnl.0000049472.47709.3b
Byrne S, Walsh C, Lynch C, Bede P, Elamin M, Kenna K, McLaughlin R, Hardiman O. Rate of familial amyotrophic lateral sclerosis: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2011;82(6):623-7. Doi: https://doi.org/10.1136/jnnp.2010.224501
Camu W, Khoris J, Moulard B, Salachas F, Briolotti V, Rouleau GA, Meininger V. Genetics of familial ALS and consequences for diagnosis. French ALS Research Group. J Neurol Sci. 1999;165 Suppl 1:S21-6. Doi: https://doi.org/10.1016/s0022-510x(99)00022-2
Pape JA, Grose JH. The effects of diet and sex in amyotrophic lateral sclerosis. Rev Neurol (Paris). 2020;176(5):301-15. Doi: https://doi.org/10.1016/j.neurol.2019.09.008
Reich-Slotky R, Andrews J, Cheng B, Buchsbaum R, Levy D, Kaufmann P, et al. Body mass index (BMI) as predictor of ALSFRS-R score decline in ALS patients. Amyotroph Lateral Scler Frontotemporal Degener. 2013;14(3):212-6. Doi: https://doi.org/10.3109/21678421.2013.770028
Lee CT, Chiu YW, Wang KC, Hwang CS, Lin KH, Lee IT, et al. Riluzole and prognostic factors in amyotrophic lateral sclerosis long-term and short-term survival: a population-based study of 1149 cases in Taiwan. J Epidemiol. 2013;23(1):35-40. Doi: https://doi.org/10.2188/jea.je20120119
Jaiswal MK. Riluzole and edaravone: A tale of two amyotrophic lateral sclerosis drugs. Med Res Rev. 2019;39(2):733-48. Doi: https://doi.org/10.1002/med.21528
Petrov D, Mansfield C, Moussy A, Hermine O. ALS Clinical Trials Review: 20 Years of Failure. Are We Any Closer to Registering a New Treatment? Front Aging Neurosci. 2017;9:68. Doi: https://doi.org/10.3389/fnagi.2017.00068
Fávero FM, Voos MC, Castro I, Caromano FA, Oliveira ASB. Epidemiological and clinical factors impact on the benefit of riluzole in the survival rates of patients with ALS. Arq Neuropsiquiatr. 2017;75(8):515-22. Doi: https://doi.org/10.1590/0004-282X20170083
Kühnlein P, Gdynia HJ, Sperfeld AD, Lindner-Pfleghar B, Ludolph AC, Prosiegel M, et al. Diagnosis and treatment of bulbar symptoms in amyotrophic lateral sclerosis. Nat Clin Pract Neurol. 2008;4(7):366-74. Doi: https://doi.org/10.1038/ncpneuro0853
Luchesi KF, Silveira IC. Palliative care, amyotrophic lateral sclerosis, and swallowing: a case study. Codas. 2018;30(5):e20170215. Doi: 10.1590/2317- https://doi.org/1782/20182017215
Panisset JA. Perfil populacional e qualidade de vida em pacientes com esclerose lateral amiotrófica (ELA) [Dissertação]. Brasília: Universidade de Brasília; 2014.
Argyriou AA, Polychronopoulos P, Papapetropoulos S, Ellul J, Andriopoulos I, Katsoulas G, et al. Clinical and epidemiological features of motor neuron disease in south-western Greece. Acta Neurol Scand. 2005;111(2):108-13. Doi: https://doi.org/10.1111/j.1600-0404.2004.00362.x
Cima V, Logroscino G, D'Ascenzo C, Palmieri A, Volpe M, Briani C, et al. Epidemiology of ALS in Padova district, Italy, from 1992 to 2005. Eur J Neurol. 2009;16(8):920-4. Doi: https://doi.org/10.1111/j.1468-1331.2009.02623.x
Forbes RB, Colville S, Parratt J, Swingler RJ. The incidence of motor nueron disease in Scotland. J Neurol. 2007;254(7):866-9. Doi: https://doi.org/10.1007/s00415-006-0454-y
Downloads
Publicado
Edição
Seção
Licença
Copyright (c) 2022 Acta Fisiátrica
Este trabalho está licenciado sob uma licença Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
